⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PYC Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
PYC Therapeutics
↗Nedlands, Australia
PYC Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics to treat genetic diseases. The company utilizes a proprietary drug delivery platform based on cell-penetrating peptides (CPPs) to overcome the challenge of delivering RNA molecules into target cells.
Headquartered in Australia, the company focuses on monogenic diseases, particularly those with high unmet medical needs in ophthalmology, the central nervous system, and the kidney. PYC is transitioning into a global clinical-stage organization with active research and clinical operations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2001
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$26M
STOCK
Exchange:ASX
Ticker:PYC
Market Cap:$0.85B
PIPELINE
Stage:Clinical
Lead Drug Stage:Phase 1
Modalities:RNA, Peptide-conjugated therapeutics
Active Trials:0
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Murdoch University (Neurodegenerative disorders research)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Rohan Hockings - CEO & Executive Director
Paula Cunningham - Chief Pre-Clinical Research Officer
Board Members:Peter John Coleman, Ian Jeffrey Constable
LINKS
Website:pyctx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PYC Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.